HIF-1: Using two hands to flip the angiogenic switch

Cancer and Metastasis Reviews

Volumn 19, Issue 1-2, 2000, Pages 59-65

  Semenza, G L ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

AKT; MAP kinase; P53; Phosphatidylinositol 3 kinase; PTEN; SRC; Vascular endothelial growth factor; Von Hippel Lindau protein

Indexed keywords

GENE PRODUCT; HYPOXIA INDUCIBLE FACTOR 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; CELL VIABILITY; EMBRYO DEVELOPMENT; GENE MUTATION; GROWTH INHIBITION; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VON HIPPEL LINDAU DISEASE;

ANIMALS; DNA-BINDING PROTEINS; ENDOTHELIAL GROWTH FACTORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHOKINES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034531766     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026544214667     Document Type: Review

References (62)

1. The hallmarks of cancer
2. Tumor progression and metastasis
3. The implication of angiogenesis for the biology and therapy of cancer metastasis
4. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
5. Tumor angiogenesis: Past, present, and the near future
6. Angiogenesis and tumor metastasis
7. Incipient angiogenesis
8. Molecular and biological properties of vascular endothelial growth factor
9. Hypoxia, clonal selection, and the role of HIF- 1 in tumor progression
10. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
11. Oxygen transport in tumors
12. Mutagenesis induced by the tumor microenvironment
13. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma
14. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
15. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo
16. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
17. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: Implications for translation under hypoxia
18. HIF-1: Mediator of physiological and pathophysiological responses to hypoxia
19. Role of HIF-1a in hypoxia-mediated apoptosis, cell proliferation, and tumour angiogenesis
20. HIF-1α is required for solid tumor formation and embryonic vascularization
21. 2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation
22. Expression of hypoxia-inducible factor 1α in human brain tumors: Association with angiogenesis, invasion, and progression
23. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases
24. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
25. Modulation of HIF-1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics
26. Loss of PTEN facilitates HIF-1-mediated gene expression
27. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas
28. The VHL tumour-suppressor gene paradigm
29. 2-dependent degradation domain via the ubiquitin-proteasome pathway
30. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway
31. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions: Its stabilization by hypoxia depends upon redox-induced changes
32. HIF-1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations
33. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
34. Hypoxia-inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein
35. p53, the cellular gatekeeper for growth and division
36. Mdm 2 promotes the rapid degradation of p53
37. Regulation of p53 stability by Mdm2
38. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors
39. Stabilization of wild-type p53 by hypoxia-inducible factor 1α
40. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
41. Release of an inhibitor of angiogenesis upon induction of wild type p 53 expression in glioblastoma cells
42. Reciprocal postive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2
43. Gene expression profiles in normal and cancer cells
44. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
45. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
46. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element
47. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma
48. Integration of positive and negative growth signals during ras pathway activation in vivo
49. Understanding Ras: 'it ain't over 'til it's over'
50. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
51. Oncogenes and tumor angiogenesis: Differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts
52. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1
53. Combined activation of ras and akt in neural progenitors induces glioblastoma formation in mice
54. Transformation by v-Src: Ras-MAPK and PI3K-mTOR mediate parallel pathways
55. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression
56. Activating SRC mutation in a subset of advanced human colon cancers
57. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src
58. Tumor angiogenesis: A physiological process or genetically determined?
59. Novel anticancer drug discovery
60. Signaltransduction cascades as targets for therapeutic intervention by natural products